Ribupatide, an experimental weekly injection, cut body weight by 20.2 percent in Chinese women with polycystic ovary syndrome. It also made their periods more regular. The second result is the one worth arguing about.
The data came out at the European Association for the Study of Diabetes meeting in Milan and was reported by BioSpace ↗ on October 2. The trial enrolled 158 women aged 18 to 40 who were overweight or obese and had polycystic ovary syndrome, now increasingly called polyendocrine metabolic ovarian syndrome, or PMOS. It was a randomized, double-blind, placebo-controlled Phase 2 study, registered as NCT06595797 ↗ and sponsored by Fujian Shengdi Pharmaceutical, a Hengrui subsidiary. After 32 weeks, weight fell 10 percent on the 1 mg dose, 15.1 percent on 2 mg, and 20.2 percent on 4 mg, against 2.6 percent on placebo. All three drug groups reported more frequent menstrual cycles over the study; the placebo group reported fewer. There were no serious adverse events and no one quit for side effects, which were mostly mild stomach complaints of the kind every drug in this class produces.
Why this population is the point
Polycystic ovary syndrome is the most common hormonal disorder in women of reproductive age. It knots together three things that feed each other: excess weight, insulin resistance (the body needing more insulin to manage blood sugar), and disrupted ovulation that shows up as irregular, infrequent, or absent periods. Weight loss is already a first-line intervention precisely because shedding weight tends to restart ovulation on its own. So testing a drug that produces some of the largest weight loss in the field, in exactly the group where weight loss is known to help the underlying problem, is a sensible bet rather than a surprising one.
That framing also sets the trap. The press-friendly version of this result is "weight-loss drug restores fertility." The honest version is narrower.
What ribupatide actually does, and does not do
Ribupatide (developer code HRS9531) activates two gut-hormone receptors at once, the GLP-1 ↗ receptor (glucagon-like peptide-1) and the GIP ↗ receptor (glucose-dependent insulinotropic polypeptide), the same dual mechanism as the approved tirzepatide ↗, sold as Mounjaro and Zepbound. Those receptors govern appetite, insulin release, and blood sugar. They do not sit on the reproductive axis. Ribupatide does not touch the receptors for gonadotropin-releasing hormone, luteinizing hormone, or follicle-stimulating hormone, the signals that actually time a menstrual cycle.
So the most likely reading of the period result is the indirect one: the drug drove large weight loss and improved insulin handling, and the menstrual cycles followed, the way they tend to follow weight loss in this condition through any route. That is a real clinical benefit for women with PMOS. It is not evidence that ribupatide has a direct effect on the ovary, and the trial was not built to separate the two.
The caveats stack up from there. One hundred fifty-eight patients is a Phase 2, not a verdict. The cohort was entirely Chinese, so the result needs replication elsewhere before it generalizes. Thirty-two weeks is short. And the menstrual outcome was something participants reported themselves rather than a hormone panel or an ovulation assay, which makes it the softest number in the readout even though it is the most interesting one.
What makes the piece worth running is the target, not the headline percentage. Ribupatide ↗ is a GLP-1/GIP dual from Hengrui, licensed to Kailera Therapeutics outside Greater China, and 20.2 percent puts it in the top tier of the class on weight alone. Pointing that tool at a metabolic-reproductive syndrome, rather than at obesity in general, is the move other developers in the GLP-1 race have not yet made in a registered trial. Whether the reproductive signal holds up in a larger, longer, hormone-measured study is the question the next readout has to answer.